A Phase 1 interventional study of CMV-MVA Triplex Vaccine in Lymphoma and Multiple Myeloma, sponsored by Masonic Cancer Center, University of Minnesota. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-17.
Sponsored by Masonic Cancer Center, University of Minnesota · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Lymphoma by Masonic Cancer Center, University of Minnesota — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Masonic Cancer Center, University of Minnesota.
Among the 31 studies in Lymphoma by Masonic Cancer Center, University of Minnesota, this one is the 15th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2018, is one of 9 in phase 1, and was the 28th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →1 of the 31 studies in Lymphoma by Masonic Cancer Center, University of Minnesota is open now, in 1 country. Recruiting first, the newest first:
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 60
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 18 · Phase 3 1
First in 1996; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 27 across the 30 interventional studies. Of the 27 that completed or were terminated, 16 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
Masonic Cancer Center, University of Minnesota is the lead sponsor of 286 studies on the registry; 35 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 28 (72%) have results posted.
1 of the studies in Lymphoma by Masonic Cancer Center, University of Minnesota that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03314974Masonic Cancer Center, University of MinnesotaMyeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | 2027-06-10 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Lymphoma by Masonic Cancer Center, University of Minnesota, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, interventional study administering 2 doses of the experimental vaccine (CMV-MVA Triplex) to 20 evaluable patients (10 CMV-seropositive and 10 seronegative) undergoing autologous hematopoietic cell transplantation (HCT) for lymphoma or myeloma on days 28 and 56 post-HCT. The absolute number of adaptive NK cells (CD56dimCD57+NKG2C+) at various days will be compared.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Planned co-enrollment on current (at the time of this study version) or future (opening subsequent to this study) standard of care stem cell transplant protocol.
* Must meet all eligibility requirements of the co-enrolled parent study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT
Biological: CMV-MVA Triplex Vaccine
CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT
Biological: CMV-MVA Triplex Vaccine
* CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT * TDap administered on Day 56
Change in the absolute number of CMV-induced adaptive NK cells (CD56dimCD57+NKG2C+) between days 28 and 100 post-auto-HCT in patients with lymphoid malignancies.
Change in the absolute number of CMV-induced adaptive NK cells (CD56dimCD57+NKG2C+) on day 28 (pre first vaccine) and day 100 (\~1 month after second vaccine) post-auto- HCT in patients with lymphoid malignancies.
Time frame: Day 28 and Day 100
Change in absolute Number of CMV-induced adaptive NK Cells
Change in absolute number of total NK and NK/T cells between days 28 (first vaccine) and day 100 (\~1 month after second vaccine) post-auto-HCT in patients with lymphoid malignancies (lymphoma and myeloma).
Time frame: Day 28 and Day 100
Response to CMV-MVA Triplex vaccine in CMV seropositive vs. seronegative patients
Change in the absolute number of adaptive NK cells between day 28 post-transplant and day 100.
Time frame: Day 28 and Day 100
Progression Free Survival (PFS)
Incidence of progression-free survival at 1 year in patients receiving CMV-MVA Triplex vaccine with historical controls
Time frame: 1 Year
Response to CMV-MVA Triplex vaccine in lymphoma vs. myeloma patients
Change in the absolute number of adaptive NK cells between day 28 post-transplant and day 100.
Time frame: Day 28 and Day 100
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2018 to primary completion in Jul 2021, 31 months.
Of 138 non-industry phase 1 interventional studies under Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 88. This study's 31 months is below that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Masonic Cancer Center, University of Minnesota →